Becker’s ASC Review sat down with Randy Whaley, director of business development for United Medical Systems, to tackle a reader’s question about what is needed for an ASC to be able to offer and ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

The 15-year OS rate was 60% among prostate brachytherapy recipients and 55% among EBRT recipients, indicating no significant difference between the arms. In prostate cancer, prostate brachytherapy (PB ...

A pooled analysis of five prospective trials showed that stereotactic body radiotherapy (SBRT) was associated with a lower risk for biochemical failure over 10 years vs high-dose rate brachytherapy ...

HDR-BT was significantly associated with increased biochemical failure risk and acute grade 2 or higher genitourinary adverse events. In men with intermediate-risk prostate cancer, stereotactic body ...

Anyone associated with ASCs is aware of the sweeping changes CMS has instituted to the facility payment system. Few specialties or procedures have undergone more changes than prostate brachytherapy.

Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ...

Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis. This is an ASCO Meeting Abstract from the 2026 ASCO ...